SCHEMBL10088973

SCHEMBL10088973

O=CC1=Cc2ccc(OCc3ccc(OCC(F)(F)F)c(Cl)c3)cc2OC1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 9/20 0.37
PPARG P37231 5/20 0.37
PPARD Q03181 3/20 0.37
MAOB P27338 4/20 0.37
MAOA P21397 3/20 0.37
ALOX5 P09917 1/20 0.36
MRGPRX4 Q96LA9 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MAPT P10636 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NPC1 O15118 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAB9A P51151 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10089019 0.90 AR (0.38) MAOBMAOAALOX5MRGPRX4MEN1
SCHEMBL10088596 0.87 FFAR1 (0.40) MAOBMAOANPC1RAB9ASMN1; SMN2
SCHEMBL10088654 0.87 MAOB (0.35) MAOBMAOAMEN1KMT2AMAPT
SCHEMBL10088469 0.85 RORC (0.36) PPARGMAOBMAOAALOX5MEN1
SCHEMBL10088921 0.85 MRGPRX4 (0.37) PPARAPPARGPPARDMAOBMAOA
SCHEMBL10088603 0.84 S1PR1 (0.46) MAOBMAOAMEN1KMT2ANPC1
SCHEMBL10088536 0.84 CSNK2A1 (0.40) MAOBMAOAMEN1KMT2A
SCHEMBL10088608 0.84 MAOB (0.40) MAOBMAOAALOX5KMT2ANPSR1
SCHEMBL10088609 0.82 CSNK2A1 (0.44) MAOBMAOA
SCHEMBL10088900 0.82 MAOB (0.55) MAOBMAOAALOX5MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2354134-B1 2H-CHROMENE DERIVATIVES AS STIMULATORS OF SPHINGOSINE 1-PHOSPHATE RECEPTOR ASTELLAS PHARMA INC (JP) 2016-02-24 EP disclosed
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2012-07-12 US disclosed
US-8193378-B2 2H-chromene compound and derivative thereof ASTELLAS PHARMA INC. (JP) 2012-06-05 US disclosed
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF ASTELLAS PHARMA INC. (JP) 2011-09-22 US disclosed
EP-2354134-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF Astellas Pharma Inc. (JP) 2011-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230463-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, CCR1 PPARA 165/4885PPARG 265/4885PPARD 148/4885
US-20120178735-A1 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF S1PR1, S1PR2, S1PR4 PPARA 99/4885PPARG 131/4885PPARD 72/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.